Details
Stereochemistry | ACHIRAL |
Molecular Formula | C24H25FN4O2 |
Molecular Weight | 420.4793 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC=CN2C(=O)C(CCN3CCC(CC3)C4=NOC5=C4C=CC(F)=C5)=C(C)N=C12
InChI
InChIKey=ZZQNEJILGNNOEP-UHFFFAOYSA-N
InChI=1S/C24H25FN4O2/c1-15-4-3-10-29-23(15)26-16(2)19(24(29)30)9-13-28-11-7-17(8-12-28)22-20-6-5-18(25)14-21(20)31-27-22/h3-6,10,14,17H,7-9,11-13H2,1-2H3
Ocaperidone [R 79598] is an equipotent antagonist of central dopamine D2 and serotonin2 receptors being investigated as a potential antipsychotic agent. Ocaperidone is a benzisoxazol piperidine antipsychotic primarily binds and with high affinity to 5-HT2 (serotonin) receptors, alpha1 and alpha 2 adrenergic receptors, dopamine D2 receptors and histamine H1 receptors. Ocaperidone is an antagonist primarily at the 5HT and D2 receptors. A proposed mechanism of action is the central D2 receptor blockade which is common to all neuroleptics that are used to treat positive symptoms of schizophrenia.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL217 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11522469 |
9.52 null [pKi] | ||
Target ID: CHEMBL5717 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11522469 |
7.55 null [pKi] | ||
Target ID: CHEMBL1983 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11522469 |
8.43 null [pKi] |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1370538
Ocaperidone was studied at various time intervals after s.c. (10 ml/kg for rats and 0.5 ml/kg for
dogs), oral (10 ml/kg for mice and rats and 0.5 ml/kg for dogs) or i.v. administration (10 ml/kg for mice, 2 ml/kg for rats and 0.5 ml/kg for dogs).
Route of Administration:
Other
Ocaperidone is an effective antipsychotic agent, acting as a potent 5-HT2 and dopamine D2 antagonist, and a 5-HT1A agonist, with Kis of 0.14 nM, 0.46 nM, 0.75 nM, 1.6 nM and 5.4 nM for 5-HT2, a1-adrenergic receptor, dopamine D2, histamine H1 and a2-adrenergic receptor, respectively, and a pEC50 and pKi of 7.60 and 8.08 for h5-HT1A.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29710
Created by
admin on Fri Dec 15 15:50:37 GMT 2023 , Edited by admin on Fri Dec 15 15:50:37 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL2104619
Created by
admin on Fri Dec 15 15:50:37 GMT 2023 , Edited by admin on Fri Dec 15 15:50:37 GMT 2023
|
PRIMARY | |||
|
SUB09395MIG
Created by
admin on Fri Dec 15 15:50:37 GMT 2023 , Edited by admin on Fri Dec 15 15:50:37 GMT 2023
|
PRIMARY | |||
|
100000083610
Created by
admin on Fri Dec 15 15:50:37 GMT 2023 , Edited by admin on Fri Dec 15 15:50:37 GMT 2023
|
PRIMARY | |||
|
FF-49
Created by
admin on Fri Dec 15 15:50:37 GMT 2023 , Edited by admin on Fri Dec 15 15:50:37 GMT 2023
|
PRIMARY | |||
|
26HUS7139V
Created by
admin on Fri Dec 15 15:50:37 GMT 2023 , Edited by admin on Fri Dec 15 15:50:37 GMT 2023
|
PRIMARY | |||
|
Ocaperidone
Created by
admin on Fri Dec 15 15:50:37 GMT 2023 , Edited by admin on Fri Dec 15 15:50:37 GMT 2023
|
PRIMARY | |||
|
6679
Created by
admin on Fri Dec 15 15:50:37 GMT 2023 , Edited by admin on Fri Dec 15 15:50:37 GMT 2023
|
PRIMARY | |||
|
71351
Created by
admin on Fri Dec 15 15:50:37 GMT 2023 , Edited by admin on Fri Dec 15 15:50:37 GMT 2023
|
PRIMARY | |||
|
129029-23-8
Created by
admin on Fri Dec 15 15:50:37 GMT 2023 , Edited by admin on Fri Dec 15 15:50:37 GMT 2023
|
PRIMARY | |||
|
DB06229
Created by
admin on Fri Dec 15 15:50:37 GMT 2023 , Edited by admin on Fri Dec 15 15:50:37 GMT 2023
|
PRIMARY | |||
|
DTXSID10156042
Created by
admin on Fri Dec 15 15:50:37 GMT 2023 , Edited by admin on Fri Dec 15 15:50:37 GMT 2023
|
PRIMARY | |||
|
C76441
Created by
admin on Fri Dec 15 15:50:37 GMT 2023 , Edited by admin on Fri Dec 15 15:50:37 GMT 2023
|
PRIMARY |
ACTIVE MOIETY